Equities analysts predict that Thermo Fisher Scientific Inc. (NYSE:TMO) will post sales of $6.78 billion for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Thermo Fisher Scientific’s earnings, with the lowest sales estimate coming in at $6.72 billion and the highest estimate coming in at $6.81 billion. Thermo Fisher Scientific posted sales of $6.51 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 4.1%. The company is scheduled to report its next quarterly earnings results before the market opens on Thursday, January 30th.
According to Zacks, analysts expect that Thermo Fisher Scientific will report full-year sales of $25.50 billion for the current financial year, with estimates ranging from $25.43 billion to $25.52 billion. For the next financial year, analysts expect that the business will post sales of $26.97 billion, with estimates ranging from $26.85 billion to $27.16 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.88 by $0.06. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The company had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.19 billion. During the same period in the previous year, the firm posted $2.62 EPS. The firm’s revenue was up 5.9% compared to the same quarter last year.
A number of analysts have recently issued reports on the stock. Wells Fargo & Co assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, January 7th. They set an “equal weight” rating and a $350.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on shares of Thermo Fisher Scientific from $315.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Credit Suisse Group assumed coverage on shares of Thermo Fisher Scientific in a report on Wednesday. They set a “neutral” rating and a $341.00 price objective for the company. Stifel Nicolaus assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, November 14th. They set a “buy” rating and a $345.00 price objective for the company. Finally, Evercore ISI raised shares of Thermo Fisher Scientific to an “outperform” rating in a report on Thursday, November 14th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $325.33.
Shares of NYSE TMO traded down $1.70 during mid-day trading on Tuesday, reaching $333.68. 945,834 shares of the company were exchanged, compared to its average volume of 1,044,165. Thermo Fisher Scientific has a 52 week low of $235.90 and a 52 week high of $342.26. The company has a quick ratio of 1.23, a current ratio of 1.80 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $136.36 billion, a PE ratio of 37.49, a PEG ratio of 2.00 and a beta of 1.12. The company’s 50 day moving average price is $326.72 and its 200 day moving average price is $299.56.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 17th were paid a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.23%. The ex-dividend date of this dividend was Monday, December 16th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.
Thermo Fisher Scientific announced that its board has authorized a stock repurchase program on Friday, November 8th that allows the company to repurchase $2.50 million in shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.
A number of institutional investors have recently bought and sold shares of the business. Clarius Group LLC raised its stake in shares of Thermo Fisher Scientific by 13.6% during the third quarter. Clarius Group LLC now owns 2,962 shares of the medical research company’s stock valued at $863,000 after acquiring an additional 355 shares during the last quarter. Karp Capital Management Corp raised its stake in shares of Thermo Fisher Scientific by 0.7% during the third quarter. Karp Capital Management Corp now owns 4,980 shares of the medical research company’s stock valued at $1,451,000 after acquiring an additional 35 shares during the last quarter. Pacitti Group Inc. bought a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $150,000. Charles Schwab Trust Co bought a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $246,000. Finally, SG Americas Securities LLC raised its stake in shares of Thermo Fisher Scientific by 484.0% during the third quarter. SG Americas Securities LLC now owns 117,249 shares of the medical research company’s stock valued at $34,151,000 after acquiring an additional 97,173 shares during the last quarter. 88.31% of the stock is owned by institutional investors and hedge funds.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: What do I need to know about analyst ratings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.